News

If granted, the FDA orphan drug designation will provide the company special development and commercial assistance, including a seven year period of marketing exclusivity. In September, the company

In the trial, SD-101 will be administered intratumorally in combination with localized low-dose radiation. The open-label, dose escalation and expansion design of the trial is intended to accelerate

The new laboratory will be used to carry out discovery and research to develop drug candidates that use new linker technologies that couple chemotherapeutic agents and proteins either

The Company will be presenting these findings today during a poster session at the American Neurological Association’s Annual Meeting in Baltimore, Maryland. Concert expects to initiate a Phase

Data were presented as a late-breaking abstract at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting in Amsterdam. The results of this study,

Palbociclib selectively inhibits cyclin-dependent kinases (CDKs) 4 and 6 to regain cell cycle control and block tumor cell proliferation. Under the new drug application (NDA), the company is

Perampanel is used as an adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. The partnership

The research program is part of a recent grant secured by PATH from the Bill & Melinda Gates Foundation to develop a model for improving the production of

The fixed combination capsule Akynzeo is distributed and marketed by Eisai, under license from Switzerland-based Helsinn Healthcare. Oral palonosetron was approved in 2008 and it prevents nausea and